Telomir Pharmaceuticals (TELO) vs. The Competition Financial Comparison

Telomir Pharmaceuticals (NASDAQ:TELO) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Telomir Pharmaceuticals to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Risk & Volatility

Telomir Pharmaceuticals has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals’ rivals have a beta of 3.86, suggesting that their average stock price is 286% more volatile than the S&P 500.

Profitability

This table compares Telomir Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-1,170.58%	-832.67%
Telomir Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Ratings

This is a breakdown of current ratings for Telomir Pharmaceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	0	0	1	1	3.50
Telomir Pharmaceuticals Competitors	8408	22247	50400	1349	2.54

Telomir Pharmaceuticals currently has a consensus target price of $15.00, suggesting a potential upside of 411.95%. As a group, “Pharmaceutical preparations” companies have a potential upside of 252.08%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Telomir Pharmaceuticals is more favorable than its rivals.

Valuation and Earnings

This table compares Telomir Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	-$16.53 million	-5.05
Telomir Pharmaceuticals Competitors	$9.89 billion	$136.37 million	-3.96

Telomir Pharmaceuticals’ rivals have higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Telomir Pharmaceuticals rivals beat Telomir Pharmaceuticals on 9 of the 13 factors compared.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.